--- title: "Metavia Collaborates with Syntekabio on AI-Driven Drug Discovery" description: "Metavia Inc. has announced positive results from its collaboration with Syntekabio, utilizing the AI-driven DeepMatcher® platform to confirm therapeutic targets for its drug candidate Vanoglipel. The " type: "news" locale: "en" url: "https://longbridge.com/en/news/274817672.md" published_at: "2026-02-04T13:02:31.000Z" --- # Metavia Collaborates with Syntekabio on AI-Driven Drug Discovery > Metavia Inc. has announced positive results from its collaboration with Syntekabio, utilizing the AI-driven DeepMatcher® platform to confirm therapeutic targets for its drug candidate Vanoglipel. The AI modeling indicates strong engagement with inflammatory and cardiometabolic targets, supporting further development for conditions like MASH and type 2 diabetes. This news is for informational purposes only and should not be considered financial or legal advice. Metavia Inc., a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced positive results from its ongoing collaboration with Syntekabio, Inc., an AI-driven drug discovery company. The partnership leverages Syntekabio’s proprietary DeepMatcher® platform to confirm key therapeutic targets for Metavia’s candidate Vanoglipel. The AI-modeling results demonstrated strong inflammatory and cardiometabolic target engagement, supporting the further development of Vanoglipel for conditions such as MASH and potentially type 2 diabetes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY77714) on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [TECH.US - Bio-Techne](https://longbridge.com/en/quote/TECH.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [MTVA.US - MetaVia](https://longbridge.com/en/quote/MTVA.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [CTKB.US - Cytek Biosciences](https://longbridge.com/en/quote/CTKB.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Inmune Bio 強調其 CORDStrom RDEB 項目及其知識產權的優勢 | INmune Bio 發佈了一份企業演示文稿，重點介紹其晚期管線，特別是針對 RDEB 的 CORDStrom 和針對神經系統疾病的 XPro1595。該公司強調其強大的專利保護，直至 2045 年，增強了其資產的商業價值。CORDStro | [Link](https://longbridge.com/en/news/277222796.md) | | IQVIA 股價上漲，因其收購了查爾斯河的早期藥物研究資產 | 合同研究公司 IQVIA Holdings 的股票在盤前上漲 2.26%，至 167.77 美元。公司表示將收購五家查爾斯河實驗室，這些實驗室專注於早期藥物發現。此次交易擴展了公司在腫瘤學、神經學、免疫學、新陳代謝和罕見疾病領域的平台。IQ | [Link](https://longbridge.com/en/news/276896365.md) | | 可穿戴設備初創公司 CUDIS 推出了一款配備 AI 驅動 “教練” 的新健康戒指系列 | 可穿戴設備初創公司 CUDIS 正在推出一系列新的健康戒指，配備 AI“代理教練”，幫助用户實現健身目標。這些戒指通過積分系統激勵健康行為，積分可兑換健康產品的折扣。AI 教練生成個性化的健康計劃，並跟蹤各種身體指標，包括睡眠質量和壓力管理 | [Link](https://longbridge.com/en/news/276929100.md) | | Tevogen 因計劃收購數字健康公司 Sciometrix 的多數股權而股價上漲 | 藥物開發公司 Tevogen 的股價在盤前交易中上漲 13.7%，至 33 美分。該公司簽署了一份意向書，計劃收購 Sciometrix 的多數股權；如果交易達成，Tevogen 將獲得 Clinicus 數字護理平台和遠程監測工具的使用權 | [Link](https://longbridge.com/en/news/277058905.md) | | 未來展望：4 位分析師對 Arcutis Biotherapeutics 的預測 | 最近對 Arcutis Biotherapeutics (NASDAQ:ARQT) 的分析師預測顯示出看漲和看跌情緒的混合。在過去三個月中，四位分析師提供了評級，平均 12 個月目標價為 34.00 美元，比之前的目標上漲了 12.4%。分 | [Link](https://longbridge.com/en/news/277080798.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.